The FDA Group's Insider Newsletter

The FDA Group's Insider Newsletter

RA/QA News Roll: Mid November 2026

Here's what's happening at FDA and across the broader life science RA/QA space.

The FDA Group's avatar
The FDA Group
Nov 19, 2026
∙ Paid

These RA/QA news rolls are available in full only to paid subscribers. Upgrade here. If you haven’t already taken our reader survey, it should only take 1 minute here.

This is our biweekly recap of news and industry happenings curated for our paid subscribers. Our goal is to bring you the headline news and the stories, research, and insights that might be harder to find.

If you haven’t upgraded to a paid subscription yet, you can do so here. Also, make sure to follow us on LinkedIn and catch the latest episodes of our podcast, The Life Science Rundown.

The FDA Group's Insider Newsletter is a reader-supported publication. To receive new posts and support our work, consider becoming a paid subscriber.

Here are some key items from the past couple of weeks.

💊 = Pharma, biologic, and biotech.
💉 = Medical device, medtech, diagnostics, and digital health.

🚨 Special Alert: Overton Nomination for FDA Commissioner Withdrawn


  • White House pulls Overton's nomination: The White House withdrew Heidi Overton's nomination for FDA commissioner just hours before the Senate HELP Committee was set to vote on it, according to reports. The move came as several Republican senators had yet to commit to supporting her. One of them, HELP Committee Chair Bill Cassidy (R-La.), said in a statement after the withdrawal that the White House had "abandoned a viable confirmation path" and that he believed "she would have had the votes to pass out of committee and pass the full Senate."

  • No clear successor as Diamantas plans to leave: Acting Commissioner Kyle Diamantas reportedly does not want to keep the job and is expected to depart before the year ends. Democrats take control of the Senate on January 3, and with few legislative days left in the current Congress, the administration has little time to pick and confirm a new nominee without bipartisan support. Reports say Sara Brenner, the FDA's former principal deputy commissioner and a three-month acting commissioner, is being considered for a return, and BioCentury reported that the administration is weighing her for a longer acting stint. Brenner currently advises Kennedy as a senior counselor and runs the National Security Council's Office of Pandemic Preparedness and Response, according to her LinkedIn page. Sen. Roger Marshall (R-Kan.), named in some reports as a candidate, is not under consideration, POLITICO reported.

  • Means attacked Overton in interviews before the withdrawal: Former White House senior adviser Calley Means called Overton "the biggest block to MAHA policies I encountered in the government" in an interview with CBS's Margaret Brennan the weekend after the midterm elections. Means said Overton deferred to then-Chief of Staff Susie Wiles and "does not have the character or integrity" to lead the FDA. He also claimed she told him and then-Commissioner Martin Makary that she could not help Makary unless he approved an mRNA flu vaccine that Makary believed should not be approved.

FDA Leadership and Administration


  • FDA chief counsel Keveney to step down: FDA Chief Counsel Sean Keveney said in a November 4 LinkedIn post that he has “decided to leave government to pursue other opportunities.” In the same announcement, he said he will stay in the role until a successor is identified and onboarded.

  • CDER and CBER post net hiring gains: CDER and CBER each grew on a net basis from July through September, based on staffing figures the FDA published. CDER’s net gain was 66 people in the final quarter of fiscal 2026, following 26 the quarter before, while CBER brought on 43 and lost 25 for its first net increase since late fiscal 2024. The FDA’s overall headcount was still down 608 for calendar 2026 through September, according to OPM data. The FDA also posted progress on its PDUFA and BsUFA hiring goals, and STAT reported in September that a shortage of HR staff has slowed onboarding. Acting Commissioner Kyle Diamantas told the Friends of Cancer Research annual meeting on November 10 that the agency is now bringing on 50 to 100 people every pay period, a pace visible in its quarterly net hiring data.

  • CDRH seeks outside consultants for reviews: 💉 CDRH posted a federal contract notice on November 2 seeking “expert consultants to assist CDRH’s Offices with regulatory review across the total product lifecycle.” The work would span pre-submission and submission reviews, sponsor meetings, and drafting reviews alongside CDRH staff, and the notice also seeks help with research, cybersecurity, digital health, and auditing. CDRH has used outside help before, but this solicitation reaches much further. The center has reported attrition of 22% to 25%, and near 30% for clinical reviewers.

  • FDA updates org charts for Simple Reform: The FDA updated its organization charts on October 30 to include the offices created under its Simple Reform reorganization. The chart for the new Office of Health Advancement, which took over from the former chief medical officer’s office, lists the OHA director job as vacant and confirms that existing office heads stay on, including James Bertram at the Office of Combination Products and Lei Xu at the Office of Orphan Products Development. Some pages still lag: the old OCMO webpage is still up, and CDRH’s Management Directory by Organization was last updated in March 2025. Changes to the federal directory have also made office-level staffing harder to see.

  • Seehafer’s title shifts to deputy commissioner for technology: Jared Seehafer’s FDA leadership page now lists him as “Deputy Commissioner for Technology” and as the agency’s chief AI, or “Super Intelligence,” officer. When he was named in September, the job was announced as deputy commissioner for technology and artificial intelligence and described as “the agency’s senior leader for technology, software, and AI.” On October 20, Seehafer was quoted with the shorter title in a press release on the FDA’s drug-connected software policy.

  • New director for the Office of User Fees: Olufunmilayo Ariyo is the new director of the FDA’s Office of User Fees, she announced in a LinkedIn post. The office sits in the Office of the Commissioner’s Office of Operations, which Melanie Keller leads.

  • Tidmarsh lawsuit targets Prasad: 💊 Former CDER Director George Tidmarsh claims in a new lawsuit that former CBER Director Vinay Prasad solicited the complaint that publicly accused him of retaliation. Tidmarsh was removed from CDER last November amid allegations that he retaliated against a drug company executive.

FDA General


  • CNPV program reportedly being phased out: 💊 The FDA is phasing out its Commissioner’s National Priority Voucher program, Reuters reported, citing six sources and internal documents. No vouchers have been granted since May 5, shortly before former Commissioner Martin Makary left and the FDA has approved 11 drugs reviewed under the program. An HHS spokesperson said FDA staff “continue to evaluate applications granted a CNPV, meet commitments for accelerated review and enhanced engagement, and assess best practices emerging from the pilot program.”

  • Potency assurance guidance finalized: 💊 The FDA finalized its guidance on potency assurance for cell and gene therapy products on November 2, replacing potency testing recommendations from 2011. The final version keeps the structure of the 2023 draft but updates its language and several sections. Sponsors get more guidance on running risk assessments, an explicit statement that potency assurance can be folded into quality risk management, and a stronger push to match their approach to where a product is in development. CBER Director Karim Mikhail said it reflects the FDA’s commitment “to ensuring America remains the best place in the world to innovate.”

  • Meeting planned on generic drug quality and confidence: 💊 The FDA and the Reagan-Udall Foundation will hold a meeting in February on “the oversight of generic prescription drugs and the perceptions that shape confidence in generic drugs.” Darby Kozak, acting director of the Office of Generic Drugs, said at the Association for Accessible Medicines’ Generics + Biosimilars Conference that public trust in generic drug quality has slipped. He pointed to a ProPublica investigation of the FDA’s approach to generic drug testing and a segment on John Oliver’s “Last Week Tonight”. “This is an opportunity for a broad range of stakeholders to weigh in on what is working, where gaps currently exist, and how we can better ensure continued patient confidence and access to high-quality, affordable medicines,” Kozak said.

  • FDA asks how to handle patient-level RWE data: 💊 The FDA issued a request for information on patient-level data requirements for drug and biologic submissions that rely on real-world data and evidence. Then-Commissioner Martin Makary said in late 2025 that the agency might stop insisting on patient-level data for such submissions. The RFI summarizes current requirements and lists obstacles, including HIPAA and the EU’s GDPR, the fact that sponsors often don’t control the databases they draw on, whether the FDA can technically take in large datasets, and data-use agreements that fit the agency’s recordkeeping rules. It asks four questions about possible solutions, and comments are due January 11.

  • Draft guidance loosens eligibility in early solid tumor trials: 💊 The FDA released draft guidance on November 10 for sponsors of early-phase solid tumor trials that urges broader patient eligibility. The FDA said restrictive criteria can “slow patient accrual, limit patient access to early-phase trials, and lead to trial results that have limited applicability in the patient population that will ultimately use the drug.” It recommends enrolling patients who have received available therapies with curative potential, dropping upper age limits, not automatically excluding patients with conditions such as brain metastases, HIV, or hepatitis, and using washout periods only when justified. The Oncology Center of Excellence guidance also addresses limiting dose toxicities, appears to build on work by Friends of Cancer Research, and is open for comment through January 11.

  • GLP-1 labels to warn of a rare eye condition: 💊 GLP-1 agonist labels must now warn of a possible higher risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare eye condition that can cause vision loss, under a new FDA requirement. The agency based the change on its meta-analysis of 126 randomized controlled trials, which found 10 probable NAION cases among GLP-1 patients and five among patients on placebo or other glucose-lowering drugs, or 6.4 versus 3.8 events per 100,000 person-years. Its Sentinel data and published observational research were also part of the review. It is not fully clear how GLP-1s could cause NAION, and some of the condition’s risk factors are the diseases the drugs treat.

  • Robotic surgery paper seeks input on remote and autonomous use: 💉 The FDA issued a discussion paper on November 6 on benefit-risk considerations for remote teleoperation and autonomous functions in robotic surgical devices. Both topics were left out of the FDA’s September draft guidance on robotically assisted surgical devices. The paper asks how an oversight framework should balance benefits against risks, what data sponsors might need to provide, and how to account for connectivity problems, cybersecurity risks, automation bias, and postmarket oversight. Comments are accepted through January 5.

  • Proposed order would downclassify oncology IHC tests: 💉 The FDA posted a proposed order on November 10 to reclassify certain immunohistochemistry test systems used with approved oncology drugs, including companion diagnostics, from Class III to Class II. The order covers 12 product codes, from tests essential to safe and effective use of a cancer drug to tests that inform a therapy’s benefits or risks in other ways. The FDA said these tests have similar enough risk profiles to fall under “the same or similar regulatory controls.” The agency said several years ago that it planned to downclassify most companion diagnostics, citing its “least burdensome” mandate. Comments are due January 11.

  • Emergency test validation guidance clears White House review: 💉 A final FDA guidance on validating diagnostic tests during emergencies has cleared review at the White House Office of Information and Regulatory Affairs. The FDA issued a draft version in January 2025 as part of its work on a testing framework for the next public health emergency, a plan that has changed over time, particularly after its laboratory-developed test rule was halted. Once published, it will sit alongside a 2025 EUA guidance on process and enforcement during emergencies.

  • FDA releases its 2027 Broad Agency Announcement: The FDA released its 2027 Broad Agency Announcement on October 30, listing 22 areas of regulatory science it is prepared to fund. Areas that appear new this year include AI to support regulatory review, nonclinical development, clinical trial modernization, onshoring manufacturing, and aging and longevity. The clinical trial section alone lists 31 actions, from trial simulation to biomarker qualification.

  • Early Alerts already top last year’s total: 💉 CDRH’s October MedSun newsletter recapped device safety news from the prior month, covering recalls and Early Alerts. The center’s Early Alert count for 2026 now stands at 109, one more than its total for all of 2025. The newsletter also pointed to an update to the FDA’s PFAS webpage and to CDRH’s collaboration with the Rare Disease Innovation Hub. MedSun is CDRH’s adverse event reporting network for device user facilities such as providers.

Compliance and Enforcement


  • Drug warning letters hit a record in fiscal 2026: 💊💉 The FDA sent 340 drug, device, and biologics warning letters in fiscal 2026, according to its compliance action data dashboard, compared with 336 the year before and 225 in fiscal 2024. Drug warning letters rose to 267 from 262, the highest of any fiscal year in the dashboard's history dating back to 2009, and 192 of them (71.9%) went to U.S.-based companies. Device letters rose to 51 from 49, while biologics letters fell to 22 from 25. Warning letters for human medical products have risen each year since fiscal 2022, with the largest increase between fiscal 2024 and 2025.

  • Most FDA inspections in India and China are now unannounced: 💊 Most FDA foreign office inspections in India and China are now unannounced, Elizabeth Miller, the FDA’s associate commissioner for inspections and investigations, said at the Association for Accessible Medicines’ Generics + Biosimilars Conference on November 3. “In India, for example, the share of FDA Foreign Office inspections conducted on an unannounced basis rose from 47% in fiscal year ‘25 to 87% in fiscal year ‘26,” Miller said. “In China, it went from 19% to 61% over the same time period.” She acknowledged difficulties “particularly at global sites where key personnel, translators or records may not be immediately available,” but said the FDA will not return to long advance notice and will instead improve its travel planning, investigator support, and clarity on records access.

  • Telehealth firm warned over “American made” GLP-1 claims: 💊 The FDA sent a warning letter to a telehealth company citing misbranding and false or misleading claims about compounded GLP-1 drugs. The FDA said the company’s social media content suggested it “is the compounder of those drugs when in fact it is not” and implied FDA approval. The agency also objected to a video calling the products “American made” and “farm-to-table drugs,” which ended with confetti bursting around an American flag, because the active ingredient was made outside the U.S. The FDA said those phrases “create the misleading impression that your products have a domestic origin indicative of superior quality.”

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2026 The FDA Group, LLC · Publisher Terms
Substack · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.